• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个新的 PTPN11 C-SH2 结构域突变导致伴有多个巨细胞病变的 Noonan 综合征。

A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.

机构信息

Plateforme GENOMAX, Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Centre de Recherche d'Immunologie et d'Hématologie. Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

1] Service d'Hématologie et Oncologie Pédiatrique, CHU Nantes, Nantes, France [2] INSERM, UMR 957, Nantes, France.

出版信息

J Hum Genet. 2014 Jan;59(1):57-9. doi: 10.1038/jhg.2013.118. Epub 2013 Nov 14.

DOI:10.1038/jhg.2013.118
PMID:24225993
Abstract

Noonan syndrome (NS), an autosomal dominant multisystem disorder, is caused by the dysregulation of the RAS-MAPK pathway and is characterized by short stature, heart defects, pectus excavatum, webbed neck, learning problems, cryptorchidism and facial dysmorphism. We here present the clinical and molecular characterization of a family with NS and multiple giant cell lesions (MGCLs). The proband is a 12-year-old girl with NS and MGCL. Her mother shows typical NS without MGCL. Whole-exome sequencing of the girl, her mother and her healthy maternal grand parents revealed a previously unobserved mutation in exon 5 of the PTPN11 gene (c.598 A>T; p.N200Y), transmitted from the mother to the proband. As no other modification in the RAS-MAPK pathway genes as related to Rasopathies was detected in the proband, this report demonstrates for the first time that a unique mutation affecting this, otherwise unaffected signaling route, can cause both NS and NS/MGCL in the same family. This observation further confirms that NS/MGCL is not a distinct entity but rather that MGCL represents a rare complication of NS. Moreover, the localization of the p.N200Y mutation suggests an alternative molecular mechanism for the excessive phosphatase activity of the PTPN11-encoded protein.

摘要

努南综合征(Noonan syndrome,NS)是一种常染色体显性多系统疾病,由 RAS-MAPK 通路失调引起,其特征为身材矮小、心脏缺陷、漏斗胸、颈蹼、学习问题、隐睾和面部畸形。我们在此报道了一个具有 NS 和多发性巨大细胞病变(multiple giant cell lesions,MGCL)的家族的临床和分子特征。先证者是一名 12 岁的女孩,患有 NS 和 MGCL。她的母亲表现出典型的 NS 但无 MGCL。对女孩、她的母亲和她健康的外祖母进行全外显子组测序,发现了 PTPN11 基因外显子 5 中一个先前未观察到的突变(c.598 A>T;p.N200Y),该突变从母亲遗传给先证者。由于在先证者中未检测到与 Ras 病相关的 RAS-MAPK 通路基因的其他修饰,因此该报告首次证明,影响这一未受影响信号通路的独特突变可导致同一家庭中同时出现 NS 和 NS/MGCL。这一观察结果进一步证实,NS/MGCL 不是一个独特的实体,而是 NS 的罕见并发症。此外,p.N200Y 突变的定位提示 PTPN11 编码蛋白的过度磷酸酶活性可能存在另一种分子机制。

相似文献

1
A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.一个新的 PTPN11 C-SH2 结构域突变导致伴有多个巨细胞病变的 Noonan 综合征。
J Hum Genet. 2014 Jan;59(1):57-9. doi: 10.1038/jhg.2013.118. Epub 2013 Nov 14.
2
Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome.努南综合征和心脏-颜面-皮肤综合征患者的多发性巨细胞病变。
Eur J Hum Genet. 2009 Apr;17(4):420-5. doi: 10.1038/ejhg.2008.188. Epub 2008 Oct 15.
3
Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation.一个携带新的PTPN11基因突变的努南综合征家族中的临床变异性。
Am J Med Genet A. 2004 Nov 1;130A(4):378-83. doi: 10.1002/ajmg.a.30270.
4
Giant cell lesions in noonan syndrome: case report and review of the literature.努南综合征中的巨细胞病变:病例报告及文献复习
Head Neck Pathol. 2010 Jun;4(2):174-7. doi: 10.1007/s12105-010-0178-2. Epub 2010 Apr 11.
5
Case report: Noonan syndrome with multiple giant cell lesions and review of the literature.病例报告:努南综合征伴多发性巨细胞病变,并文献复习。
Am J Med Genet A. 2012 Sep;158A(9):2283-9. doi: 10.1002/ajmg.a.35493. Epub 2012 Jul 27.
6
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.患者存在 SHOC2 和 PTPN11 共有的突变,表现为严重/复杂类诺南综合征表型。
Am J Med Genet A. 2011 Jun;155A(6):1217-24. doi: 10.1002/ajmg.a.33987. Epub 2011 May 5.
7
Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.一种导致努南综合征的新型PTPN11突变簇的结构、功能及临床特征
Hum Mutat. 2017 Apr;38(4):451-459. doi: 10.1002/humu.23175. Epub 2017 Feb 7.
8
SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.5例伴有多发性巨细胞病变的努南综合征中的SOS1和PTPN11突变
Eur J Hum Genet. 2009 Oct;17(10):1216-21. doi: 10.1038/ejhg.2009.44. Epub 2009 Apr 8.
9
Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.107 名诺南综合征患者 PTPN11 突变的分子和临床研究。
BMC Med Genet. 2020 Mar 12;21(1):50. doi: 10.1186/s12881-020-0986-5.
10
Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.对埃及努南综合征患者 PTPN11 基因的突变分析。
J Formos Med Assoc. 2013 Nov;112(11):707-12. doi: 10.1016/j.jfma.2012.06.002. Epub 2012 Aug 1.

引用本文的文献

1
Giant Cell Lesions of the Jaws Involving RASopathy Syndromes.累及RAS病综合征的颌骨巨细胞病变
Acta Stomatol Croat. 2022 Mar;56(1):77-88. doi: 10.15644/asc56/1/9.
2
Imatinib, a New Adjuvant Medical Treatment for Multifocal Villonodular Synovitis Associated to Noonan Syndrome: A Case Report and Literature Review.伊马替尼——一种用于治疗与努南综合征相关的多灶性色素沉着绒毛结节性滑膜炎的新型辅助药物治疗:病例报告及文献综述
Front Med (Lausanne). 2022 Jan 17;8:817873. doi: 10.3389/fmed.2021.817873. eCollection 2021.
3
miRNA Genetic Variants Alter Their Secondary Structure and Expression in Patients With RASopathies Syndromes.

本文引用的文献

1
Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.RIT1 中的功能获得性突变导致努南综合征,一种 RAS/MAPK 通路综合征。
Am J Hum Genet. 2013 Jul 11;93(1):173-80. doi: 10.1016/j.ajhg.2013.05.021. Epub 2013 Jun 20.
2
Noonan syndrome.努南综合征。
Lancet. 2013 Jan 26;381(9863):333-42. doi: 10.1016/S0140-6736(12)61023-X. Epub 2013 Jan 10.
3
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
微小RNA基因变异改变其在RAS病综合征患者中的二级结构和表达。
Front Genet. 2019 Nov 13;10:1144. doi: 10.3389/fgene.2019.01144. eCollection 2019.
甲磺酸伊马替尼治疗局部晚期和/或转移性腱鞘巨细胞瘤/色素绒毛结节性滑膜炎的疗效。
Cancer. 2012 Mar 15;118(6):1649-55. doi: 10.1002/cncr.26409. Epub 2011 Aug 5.
4
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.RAS-MAPK 信号通路失调导致的疾病:表型谱和分子机制。
Ann N Y Acad Sci. 2010 Dec;1214:99-121. doi: 10.1111/j.1749-6632.2010.05790.x. Epub 2010 Oct 19.
5
Noonan syndrome: clinical aspects and molecular pathogenesis.努南综合征:临床特征与分子发病机制
Mol Syndromol. 2010 Feb;1(1):2-26. doi: 10.1159/000276766. Epub 2010 Jan 15.
6
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.RAS病:Ras/丝裂原活化蛋白激酶(MAPK)信号通路失调所致的发育综合征
Curr Opin Genet Dev. 2009 Jun;19(3):230-6. doi: 10.1016/j.gde.2009.04.001. Epub 2009 May 19.
7
SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.5例伴有多发性巨细胞病变的努南综合征中的SOS1和PTPN11突变
Eur J Hum Genet. 2009 Oct;17(10):1216-21. doi: 10.1038/ejhg.2009.44. Epub 2009 Apr 8.
8
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).伊马替尼对复发性色素沉着绒毛结节性滑膜炎/腱鞘巨细胞瘤(PVNS/TGCT)的完全缓解。
Ann Oncol. 2008 Apr;19(4):821-2. doi: 10.1093/annonc/mdn033. Epub 2008 Feb 21.
9
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.《Shp'ing新闻:细胞信号传导中含SH2结构域的酪氨酸磷酸酶》
Trends Biochem Sci. 2003 Jun;28(6):284-93. doi: 10.1016/S0968-0004(03)00091-4.
10
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.努南综合征中的PTPN11突变:分子谱、基因型-表型相关性及表型异质性
Am J Hum Genet. 2002 Jun;70(6):1555-63. doi: 10.1086/340847. Epub 2002 May 1.